|
|
|
|
Дата |
|---|
| 21:17 |
| 08.01.2026 |
| 07.01.2026 |
| 06.01.2026 |
| 05.01.2026 |
| 02.01.2026 |
| 31.12.2025 |
| 30.12.2025 |
| 29.12.2025 |
| 26.12.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
3.67
|
3.68
|
3.83
|
3.63
|
3.83
|
3.67
|
|
|
136 466.52
|
625.00
|
|
3.76
|
3.89
|
3.95
|
3.71
|
3.95
|
3.80
|
|
|
376 962.93
|
755.00
|
|
4.00
|
4.05
|
4.00
|
3.90
|
4.03
|
4.00
|
|
|
759 425.12
|
1 086.00
|
|
3.86
|
4.04
|
5.13
|
3.81
|
5.15
|
3.87
|
|
|
1 573 771.79
|
2 913.00
|
|
4.29
|
4.41
|
4.37
|
4.13
|
4.395
|
4.37
|
|
|
443 939.05
|
731.00
|
|
4.16
|
4.40
|
4.19
|
4.15
|
4.37
|
4.27
|
|
|
496 895.59
|
430.00
|
|
3.95
|
4.15
|
4.00
|
3.93
|
4.05
|
3.98
|
|
|
211 783.34
|
277.00
|
|
3.90
|
4.30
|
4.05
|
3.93
|
4.18
|
3.95
|
|
|
203 840.12
|
409.00
|
|
4.01
|
4.09
|
4.34
|
3.91
|
4.36
|
4.02
|
|
|
362 066.57
|
638.00
|
|
4.30
|
4.46
|
4.615
|
4.32
|
4.63
|
4.335
|
|
|
241 394.01
|
519.00
|
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Показать все Скрыть